Cancer Therapy Powered By You™

SYNC-T

SOLID TUMOR

TREATMENT

PLATFORM

Synchronizing In Situ Neoantigen T Cell Education And Immunostimulation Via Drug / Device Combination Therapy

™

SOLID TUMORS PRESENT MULTIPLE CHALLENGES FOR CURRENT THERAPIES

CAR-T

CAR-T targets a specific tumor antigen which is highly effective in treating liquid tumors (blood cancers)

Conversely, solid tumors have a high degree of tumor antigen heterogeneity and hence a targeted antigen approach is not effective

In addition, lack of T cell trafficking & infiltration, T cell exhaustion, and numerous immunosuppressive mechanisms prevent CAR-T from being effective in treating solid tumors

SYSTEMIC IMMUNOTHERAPY

Current systemically administrated immunotherapies have been a major advance for the treatment of metastatic cancer patients. However, despite these major advances, only 15% - 20% of patients respond to systemic immunotherapy^{1^.}

Unfortunately, most patients (80% - 85%) with metastatic cancer still do not benefit from systemic immunotherapies and succumb to their cancer.

CAR-T has been highly effective in liquid tumors but has shown limited responses in solid tumors^{2^.}

Syncromune™ is developing the SYNC-T™ platform to specifically overcome these challenges with a disruptive combination approach that aims to optimize T cell education and empower the immune system to attack cancer.

In Situ T Cell Education & Immunostimulation.

To overcome these barriers, Syncromune® is developing SYNC-T™, a disruptive personalized in situ platform drug immunotherapy to educate T cells and stimulate the immune system to treat metastatic solid tumors where other therapies have failed. The proprietary platform therapy aims to synchronize in situ neoantigen T cell education and immunostimulation to empower the immune system to attack cancer throughout the body.

TARGETING METASTATIC SOLID TUMORS

Our platform therapy, SYNC-T™, has the potential to treat numerous types of metastatic solid tumors due to the fact its mechanism of action is not dependent on the solid tumor cancer type or the specific tumor antigens they express. Our initial solid tumor focus is metastatic prostate cancer, breast cancer, and non-small cell lung cancer.

NSC LUNG CANCER

2022 U.S. DEATHS: 130,180

BREAST CANCER

2022 U.S. DEATHS: 43,250

PROSTATE CANCER

2022 U.S. DEATHS: 34,500

Source: American Cancer Society. Cancer Facts & Figures 2022. Atlanta: American Cancer Society; 2022.

SYNC-T™ PIPELINE

Our current pipeline focuses on treating metastatic solid tumors utilizing the SYNC-T™ platform.

Johns Hopkins Health. Immunotherapy: Precision Medicine in Action. Hopkinsmedical.org. Accessed 28 October 2022. https://www.hopkinsmedicine.org/inhealth/about-us/immunotherapy-precision-medicine-action-policy-brief.html#:~:text=Immunotherapy%20drugs%20work%20better%20in,are%20about%2015%20to%2020%25.
Lui G, et al. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cellular & Molecular Immunology (2021) 18:1085-1095.

Disclaimers: The content on this website is intended for US healthcare professionals only. The compounds and their uses mentioned on this website are investigational and have not been determined safe and effective by the US Food and Drug Administration.